What is the fair value of ABBV?

Based on inv-AI’s institutional-grade analysis, the 12-month fair value estimate for AbbVie Inc. (ABBV) is $210 (range: $178–$242). Confidence level: MEDIUM.

Is ABBV overvalued or undervalued?

AbbVie Inc. (ABBV) is rated Fairly Priced (Low) by inv-AI. The current price is $205.2 versus a mid fair value of $210, implying +2.3% upside.

What is the ABBV price target for 2026?

inv-AI’s 2026 fair value range for AbbVie Inc. (ABBV) is $178 (bear) to $242 (bull), with a base case of $210.

AbbVie Inc. (ABBV) Valuation

Rating: Fairly Priced (Low)

12-Month Fair Value: $178 – $210 – $242

Confidence: MEDIUM

AbbVie has executed the most successful patent cliff navigation in pharma history. Skyrizi/Rinvoq ($25.9B FY2025, +30%) surpassed peak Humira ($21.2B) a year early. At $222 (15.3x forward EPS), the stock is fairly priced for diversified pharma growing 9.5% with $18.5B FCF and 3.1% dividend yield. Near-term R/R neutral (0.71:1); long-term favorable (1.65:1, ~4.7% total CAGR). HOLD; accumulate below $180.

View full report | All intelligence | Home